INVOLVEMENT OF THE CALCIUM-SENSING RECEPTOR IN HUMAN TASTE PERCEPTION

Takeaki Ohsu1, Yusuke Amino2, Hiroaki Nagasaki3, Tomohiko Yamanaka3, Sen Takeshita1, Toshihiro Hatanaka1, Yutaka Maruyama4, Naohiro Miyamura3 and Yuzuru Eto1,4
From Pharmaceutical Research Laboratories1, AminoScience Laboratories2, Food Products Company3 and Institute of Life Sciences4, Ajinomoto Co., Inc.
1-1, Suzuki-cho, Kawasaki-ku, Kawasaki 210-8681, Japan
Address correspondence to: Yuzuru Eto, 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki 210-8681, Japan. FAX: +81-44-210-5871; E-mail: yuzuru_eto@ajinomoto.com

By means of human sensory analyses, we found that various extracellular calcium-sensing receptor (CaSR) agonists enhance sweet, salty, and umami tastes, though they have no taste themselves. These characteristics are known as “kokumi taste”, and often appear in traditional Japanese cuisine. Although glutathione (GSH) is a typical kokumi taste substance (taste enhancer), its mode of action is poorly understood. Here, we demonstrate how the kokumi taste is enhanced by the CaSR, a close relative of the class C G-protein-coupled receptors T1R1, T1R2, and T1R3 (sweet and umami receptors). We identified a large number of CaSR agonist γ-glutamyl peptides, including GSH (γ-Glu-Cys-Gly) and γ-Glu-Val-Gly, and showed that these peptides elicit the kokumi taste. Further analyses revealed that some known CaSR agonists such as Ca2+, protamine, polylsine, L-histidine, and cinacalcet (a calcium mimetic drug), also elicit the kokumi taste, and that the CaSR-specific antagonist, NPS-2143, significantly suppresses the kokumi taste. This is the first report indicating a distinct function of the CaSR in human taste perception.

The extracellular calcium-sensing receptor (CaSR)(1) is a class C G-protein-coupled receptor (GPCR) consisting (in humans) of 1078 amino acids. It plays a central role in extracellular calcium homeostasis in mammals(2). An increase in the blood calcium level is sensed by the CaSR, which in turn suppresses parathyroid hormone secretion, stimulates the secretion of calcitonin, and induces urinary calcium excretion to reduce blood calcium to normal levels. It has become apparent that the CaSR is expressed not only in the parathyroid glands and kidneys, but also in many other tissues, such as the liver, heart, lungs, alimentary canal, lymphocytes, pancreas, and the central and peripheral nervous systems, thus suggesting that it is involved in a range of biological functions(3). Several types of substances have been reported to possess CaSR activity, including cations such as Ca2+ and Gd3+, basic peptides such as protamine and polylsine, and polyamines such as spermine(3). In
and hearty. The *kokumi* taste was first characterized by Ueda et al., who isolated a *kokumi* taste substance from water extracts of garlic and onion, and identified GSH as the main active ingredient(9,10). GSH itself is tasteless; however, in the presence of small amounts of umami taste substances such as monosodium glutamate (MSG) and inosine monophosphate (IMP), GSH synergistically reinforces those tastes.

In this report, we demonstrate that the CaSR is involved in *kokumi* taste perception in humans and report the discovery of various CaSR agonist peptides, including gamma-glutamyl-valyl-glycine (γ-Glu-Val-Gly), a potent *kokumi* taste substance.

**Experimental Procedures**

**Chemicals** The CaSR agonists used in the human sensory analyses were commercially available, food additive products such as calcium lactate (Sky Food), protamine (Asama Chemicals), and polylysine (Nihon Chisso). Cinacalcet(13) and NPS-2143(14) were chemically synthesized by methods described in the literature, and their activity was determined by HEK-293 cells that were transiently transformed with the human CaSR (hCaSR). All other reagents were of special purity grade purchased from Sigma Aldrich Japan.

**Peptides** The following peptides were used in the study: γ-Glu-Cys-Gly (GSH; Sigma Aldrich), γ-Glu-Cys(SNO)-Gly (Dojin...
Chemical Laboratory), γ-Glu-Ala (Bachem Feinchemikalien), γ-Glu-Gly (Bachem Feinchemikalien AG), γ-Glu-Cys (Sigma Aldrich), γ-Glu-Met (Bachem Feinchemikalien AG), γ-Glu-Abu-Gly (Abu, α-aminobutyric acid; Bachem Feinchemikalien AG), γ-Glu-Thr (Kokusan Chemical), and γ-Glu-Val (Kokusan Chemical). Other peptides were chemically synthesized and purified by a contract manufacturer, using well-known techniques. Solutions of the glutamine- and cysteine-containing peptides were prepared immediately before use, whereas those of other peptides were stored at −20°C after preparation. In the case of acidic and alkaline substances, the solutions were adjusted to pH 7.0–7.4 by the addition of NaOH or HCl. The CaSR agonists and antagonist used in this study are listed in Supplementary Table 1.

Preparation of cRNA- cRNA of the hCaSR was prepared from human kidney cDNA (Clontech), using a PCR method. Briefly, primer oligo-DNAs [forward primer (N:ACTAATACGACTCACTATAGGGACCATGGCATTTTATAGCTGCTGG) and reverse primer (C:TTATGAATTCACTACGTCTCTTCTGTAAC AG); NCBI NM_000388] were synthesized, and PCR was performed using Pfu ultra DNA Polymerase (Stratagene) under the following conditions. After an initial reaction at 94°C for 3 min, a cycle of reactions at 94°C for 30 s, 55°C for 30 s, and 72°C for 2 min was repeated 35 times, and then a final reaction was performed at 72°C for 7 min. The plasmid vector pBR322 (Takara) was digested with the restriction enzyme EcoRV. The PCR product was ligated to the EcoRV cleavage site of the plasmid pBR322 (Takara), using a ligation kit (Promega). hCaSR cRNA was synthesized using a cRNA preparation kit with this sequence as a template (Ambion).

Determination of CaSR activity using oocytes- CaSR agonist-induced currents were characterized using oocytes microinjected with hCaSR cRNA. Briefly, Xenopus laevis ovarian lobes were surgically removed, defolliculated, and treated with collagenase II. Oocytes were then microinjected with 10–20 ng of hCaSR cRNA, and incubated for 36–48 h at 15°C in Barth’s solution. The activation of CaSR (Gq class GPCR) expressed in oocytes leads to an increase in intercellular calcium ions. This increase in free calcium activates oocyte endogenous calcium dependent chloride channels, concomitantly with a measurable current. The oocytes were impaled by two electrodes in a voltage-clamp configuration with a Geneclamp 500 (Axon), and responses were recorded using AxoScope 9.0 recording software (Axon) at −70 mV membrane potential. The oocytes were challenged with 0.1–1000 µM solutions of CaSR agonists in a perfusion buffer containing 96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, and 5 mM Hepes (pH 7.2), and the peak recorded current was deemed the strength of receptor activation.
Determination of CaSR activity using HEK-293 cells. hCaSR cDNA was constructed in an expression vector, pcDNA3.1, and transiently transfected into HEK-293 cells. Briefly, the cDNA was diluted with Opti-MEM medium (Invitrogen), mixed with FuGENE6 (Roche), and poured onto HEK-293 cells grown at a sub-maximum concentration. After 24 h of culture in a 96-well plate, the cells were incubated with 5 µM Calcium-4 (Calcium-4 Assay Kit; Molecular Devices) for 45–60 min, and measurements were conducted using an image analyzer (Flex-Station; Molecular Devices) and its associated software. The activation of CaSR expressed in HEK cells lead to an increase in intercellular calcium ions. This increase in free calcium was determined by calcium dye Calcium-4. The dye binds the free Ca\(^{2+}\) resulting in an increase in dye fluorescence, which is excited at 485 nm and emits at 525 nm. Concentration dependence of the fluorescence intensity was analyzed with various CaSR agonists, with or without 0.0002% (4.5 μM) NPS-2143. The assay buffer for calcium imaging contained a 0.9 mM concentration of CaCl\(_2\).

Continuous kokumi taste sensory analyses of GSH and γ-Glu-Val-Gly. Time-course profiles of the kokumi taste of GSH (0.08%) and γ-Glu-Val-Gly (0.01%) were determined by continuous human sensory analyses. Briefly, the test samples contained low concentrations of umami and salty tastes (0.02% MSG, 0.02% IMP, and 0.07% NaCl), with or without kokumi taste substances. The test sample (20 mL) was administered orally, and the taste assessors were instructed to keep the sample in their mouths for at least 30 s, during which, the taste intensity was expressed as a percentage score in comparison with the maximum intensity obtained with a standard solution containing 0.7% MSG and 0.5% NaCl, which was taken as 100%. Data were recorded every second. The analyses were performed by a panel of 20 well-trained assessors.

Kokumi taste determination by human sensory analyses with a 5-point rating scale. Samples were dissolved in distilled water and adjusted to pH 6.8-7.2 with NaOH. The human sensory analysis of a sample solution was performed by a previously described method(9). A well-trained panel of 20 assessors was asked to evaluate the sample solutions on a 5-point rating scale, from −2 (apparently suppressed) to +2 (apparently strong). Kokumi taste in each basic taste solution was estimated by the thickness, a measure of the taste intensity 5 s after tasting. The results were analyzed by the Student’s \(t\) test. The kokumi taste in the presence of each basic taste, i.e., sweet, salty, or umami was determined with GSH (0.1%) or γ-Glu-Val-Gly (0.01%) mixed with sucrose (3.3%), NaCl (0.9%), or MSG (0.5%), respectively. The presence of the kokumi taste in foodstuffs was determined as follows. Consommé containing 2% commercial chicken consommé powder (Ajinomoto) was prepared. GSH (0.02%), γ-Glu-Val-Gly (0.002%), and γ-Glu-Val-Leu
(0.02%; a low activity control peptide) were then dissolved in the consommé. The kokumi taste was determined for three paired scale terms: thickness, continuity, and mouthfulness. Thickness was expressed in terms of increased taste intensity at approximately 5 s after tasting, continuity was expressed as the taste intensity at around 20 s, and mouthfulness was expressed as the reinforcement of the taste sensation throughout the mouth, and not just on the tongue. Known CaSR agonists and an antagonist were used at the following final concentrations: calcium lactate (0.35%), protamine (0.02%), polylysine (0.08%), L-histidine (0.2%). Cinacalcet was dissolved in 99.5% ethanol at a concentration of 1% and then diluted to 0.0015% (38 μM) with the tasting solution for sensory analysis. NPS-2143 was dissolved in 99.5% ethanol at a concentration of 0.1% and then diluted to 0.0002% (4.5 μM) with the tasting solution. The remaining ethanol in the tasting solution did not affect the sensory analysis evaluation. Methods used in the human sensory analyses were approved by the Management Committee of Food Product Application Center at Ajinomoto Co., Inc. Japan, and informed consent was obtained from all assessors.

Quantitative analyses of kokumi taste compared with the GSH kokumi standard. Quantitative analyses were conducted to compare taste thickness. The strength of the kokumi taste was evaluated as a PSE as follows. Test samples of γ-Glu-Cys (0.15%), γ-Glu-Val (0.15%), γ-Glu-Ala (0.5%), γ-Glu-Abu-Gly (0.05%), or γ-Glu-Val-Gly (0.01%) were mixed with umami and salty taste solutions (0.05% MSG, 0.05% IMP, and 0.5% NaCl), and their tastes were compared with those of various concentrations of GSH as reference solutions. Ten concentrations of GSH in logarithmically equal steps at 50% intervals were used (0.02, 0.03, 0.044, 0.07, 0.10, 0.15, 0.23, and 0.34% w/v). Each test sample was paired twice with each reference solution. Assessors judged the PSE between the sample and reference solutions. All judgments were dichotomous: i.e., the assessors were required to rate a test sample as either more or less intense than the reference GSH solution. The PSE was defined as the concentration that was judged to give a sensation that was equivalent to that of the standard solution. The analyses were performed by a panel of 17 well-trained assessors.

RT-PCR analyses of mRNA extract of mouse taste buds. C57BL/6N mice (6-week-old males, Charles River) were sacrificed by cervical dislocation. RT-PCR amplification was performed using primers that amplify mouse (m-) CaSR, m-T1R2, and m-β-actin. Briefly, tissues containing circumvallate or foliate papillae were injected into the submucosal layer with a mixture of 1 mg/mL collagenase A (Roche), 2.5 mg/mL dispase II (Roche), and 1 mg/mL trypsin inhibitor (Sigma Aldrich) and then incubated for 20 min at room temperature. The papillae-containing epithelium was then peeled from the underlying connective
tissue. The total RNA was isolated from the epithelial papillae and from the epithelium without taste buds (RNA micro kit: Stratagene). The purified RNA was denatured at 60°C for 5 min, and first-strand cDNA was synthesized at 50°C for 60 min using oligo dT12-18 primer and reverse transcriptase (SuperScript III; InVitrogen) in a final volume of 20 µL. After synthesizing the cDNA, 1 µL of cDNA was used as a template in 20 µL of PCR mixture with tag polymerase (InVitrogen). The PCR conditions were as follows: 94°C for 2 min, and 29–35 cycles at 94°C for 30 s, 58°C for 20 s, and 72°C for 45 s. The PCR products were analyzed by gel electrophoresis (2% agarose gel) with Gel-Red staining (Biotium). The primers used were as follows: m-CaSR, 5′-TCGAGACCCCTTACATGGAC-3′ (forward) and 5′-AGTAGTTTCCCACCAGGTCA-3′ (reverse); m-T1R2, 5′-TGGCAGCTACTCAGGGAGAT-3′ (forward) and 5′-GGACAGTCCACACACTCGAA-3′ (reverse); and m-β-actin, 5′-CACCCGTGCTGCTACACC-3′ (forward) and 5′-GCACGATTTCCTCTCATG-3′ (reverse). The methods used in this study were approved by the Institutional Animal Care and Use Committee at Ajinomoto Co., Inc., Japan.

RESULTS

**Discovery of CaSR agonist gamma-glutamyl peptides** We screened di- and tri-peptide libraries for CaSR activity and discovered 46 γ-glutamyl (γ-Glu) peptides, including GSH (γ-Glu-Cys-Gly) (Table 1). Among them, γ-Glu-Val-Gly had the most potent CaSR activity. Amino acids have been reported to bind to the large, extracellular Venus flytrap domain (VFD) of the CaSR, a structure common to all members of class C GPCRs. It was suggested that all amino acids bind at the VFD binding-pocket, through the amino and carboxyl groups(5). This binding motif is common to free amino acids and γ-Glu peptides [γ-glutamic acid (γ-Glu) at the N end]. In contrast, substitution of the γ-Glu residue with β-Asp or β-Ala resulted in loss of activity (data not shown). Furthermore, those γ-Glu tripeptides with a large hydrophobic acid, a basic acid, or an acidic amino acid at the second position were inactive. A thiol group of cysteine at the second position was not essential for CaSR activity. The third-position analogues of γ-Glu-Val-Gly were active, except for Ile, Trp, Tyr, and β-Ala. The presence of the third-position residue, especially one with a free carboxyl terminal and no side chain (Gly), substantially enhanced activity. These results indicate that an exact alignment and the presence of two charged groups in the NH2-terminal residue are required for CaSR binding. The putative interaction between γ-Glu-Val-Gly and the L-amino acid binding site of the CaSR is illustrated in Supplementary Fig. 1.
Because GSH is a known authentic *kokumi* taste substance, we evaluated whether or not the newly identified CaSR agonist peptides γ-Glu-Val-Gly could impart a *kokumi* taste. Short-term time-course profiles of the *kokumi* taste of GSH and γ-Glu-Val-Gly were determined by human sensory analyses (Fig. 1). In the case of control solutions containing low concentrations of umami and salty substances, the taste intensity increased after oral administration at 0 s, peaked at around 10 s, and then decreased over a 40-s period. The peak intensity was significantly elevated (i.e., doubled) in the presence of GSH or γ-Glu-Val-Gly, and this elevation remained distinct even after 20 s.

**Kokumi taste intensity of GSH and γ-Glu-Val-Gly.** We tested the *kokumi* taste effects of GSH and γ-Glu-Val-Gly on the basic tastes (sweet, salty, and umami) and found a significant enhancement as shown in Fig. 2A, though they have no taste themselves (data not shown). The intensity of taste enhancement was graded as follows: 0 points for no intense activity, 1 point for fairly intense activity, and 2 points for intense activity. In this study, enhancement of *kokumi* taste (so called “thickness”) was measured. Sensory analysis of γ-Glu-Val-Gly was performed at a concentration of 0.01%, one-eighth that of GSH.

Further examination was performed to reveal the enhancement of *kokumi* taste when the CaSR agonist peptides were mixed with a foodstuff. The *kokumi* taste intensity of γ-Glu-Val-Gly and GSH was much more significant when the peptides were mixed into a solution such as chicken consommé as a result of the coexistence of various flavors that taste sweet, umami, and salty (Fig. 2B). γ-Glu-Val-Gly enhanced all three *kokumi* taste characteristics (thickness, continuity, and mouthfulness). γ-Glu-Val-Gly produced a potent *kokumi* taste at a concentration as low as 0.002%, whereas γ-Glu-Val-Leu (a low-activity control peptide) produced a faint *kokumi* taste (Fig. 2B).

Because GSH has an aroma that is based on the sulfur atom of Cys, it seemed that the smell was related to the *kokumi* taste(15). It is known that GSH is contained in many kinds of foods, especially meat, and that the hydrogen sulfate derived from cysteine produces a sulfur odor(16). GSH reinforced the aroma, but γ-Glu-Val-Gly did not. However, γ-Glu-Val-Gly produced a *kokumi* taste, even though its second amino acid is Val instead of Cys. These results suggest that the *kokumi* taste is integrated into the taste sensory system and is independent of the olfactory sensory system.

**Quantitative CaSR activity of γ-Glu peptides.** Detailed dose-response curves were determined using HEK-293 cell assays for 6 of the 46 γ-Glu peptides identified as CaSR agonists. Fluorescence intensities observed with these peptides were 26–53% of the maximum intensity observed with Ca$^{2+}$ or cinacalcet (Fig. 3A, Supplementary Fig. 2). The effective concentration values (EC$_{50}$) for the γ-Glu peptides, which correspond to the concentrations that
produced 50% of the maximum intensity, are as follows: γ-Glu-Ala (3.65 μM/42.6 = E_{max} for Ca^{2+}), γ-Glu-Val (1.34 μM/53.3), γ-Glu-Cys (458 nM/38.0), γ-Glu-Cys-Gly (76.5 nM/27.6), γ-Glu-Abu-Gly (18.1 nM/25.6), and γ-Glu-Val-Gly (41.9 nM/40.8).

Correlations between CaSR activity and kokumi taste intensity of γ-Glu peptides: A quantitative sensory evaluation of kokumi taste was performed with the six γ-Glu peptides, and the results were expressed as points of subjective equivalence (PSEs) for each γ-Glu peptide test solution in relation to that of the reference solution, GSH(9). The intensity of the kokumi taste was quantified in terms of the GSH concentration required to attain an equal intensity of sensation. γ-Glu-Val-Gly had the most potent kokumi taste; a 0.01% solution produced a kokumi taste equivalent to a GSH concentration of 0.128%. Therefore, we estimated that the kokumi taste of γ-Glu-Val-Gly is 12.8 times stronger than that of GSH. All five CaSR agonist peptides tested against GSH were confirmed to have kokumi taste (Table 2). CaSR activity was investigated in detail, using HEK-293 assays to determine EC_{50} values (Fig. 3A). A significant correlation was observed between CaSR activity and kokumi taste intensity when the intensities were expressed as a value relative to that of GSH and was plotted in two dimensions on a logarithmic scale (Fig. 3B). These peptides were randomly chosen from the CaSR agonist peptides listed in Table 1. These results strongly suggest that the CaSR is involved in the perception of kokumi taste in humans.

Kokumi taste intensity of known CaSR agonists and the effect of the antagonist: We determined the kokumi taste of known CaSR agonists and the inhibitory effect of the synthetic CaSR antagonist, NPS-2143. Although calcium lactate, protamine, polylysine, and L-histidine are used as food additives, it is not known whether they have their own taste. Cinacalcet, a chemically synthesized allosteric activator of the CaSR, is useful as a drug for the treatment of secondary hyperparathyroidism and hypercalcemia. In our tests, calcium lactate, protamine, polylysine, L-histidine, and cinacalcet showed significant kokumi taste enhancement at concentrations of 0.35%, 0.02%, 0.08%, 0.2%, and 0.0015%, respectively (Fig. 4A). Some of these substances had bitter tastes at higher concentrations but were suitable for analysis when tested under our conditions. In contrast, the tested CaSR agonist peptides did not possess a bitter taste at any concentration, even though kokumi taste intensity was evaluated by human sensory analyses over a wide range of concentrations.

Human sensory analyses were performed to determine if the kokumi tastes of GSH and γ-Glu-Val-Gly were suppressed in the presence of 0.0002% (4.5 μM) NPS-2143 (Fig. 4B). NPS-2143 is a CaSR-specific antagonist that effectively inhibits the activity of both GSH (Data not shown) and γ-Glu-Val-Gly (Fig. 3C). These results clearly indicate that
the CaSR is involved in *kokumi* taste perception in humans.

*Expression of the CaSR in the peripheral taste tissue*: Reverse transcription polymerase chain reaction (RT-PCR) analyses in mice have demonstrated that mRNA of the CaSR and T1R2, as the control for taste cells, are expressed in taste buds containing epithelium of the circumvallate and foliate papillae. The RT-PCR products for the CaSR were not found in the epithelium surrounding the papillae (Supplementary Fig. 2). These findings suggest that the CaSR could be a *kokumi* taste receptor involved in taste perception. On the other hand, mRNA expression for GPRC6A, which is the closest relative gene of the CaSR, was not detected in both circumvallate and foliate papillae in our experiments with four independent sets of primers.

**DISCUSSION**

Taste plays a crucial role in the response to sweet, bitter, sour, salty, and umami stimuli and in the detection of nutritional status. These stimuli are believed to be recognized by specific receptors and transduction pathways. It has previously been shown that the sweet receptor is a heterodimer of T1R2 and T1R3(17,18), the umami receptor is a heterodimer of T1R1 and T1R3(17,19), and the bitter receptors are a family of T2Rs(20,21). The epithelial sodium channel(22) and transient receptor potential family members PKD1L3 and PKD2L1(23) are plausible candidates as receptors for the salty and sour (acid) tastes, respectively. A common characteristic of *kokumi* taste substances, such as GSH, is that they are tasteless by themselves, but enhance basic tastes. Because GSH appears on the list of identified CaSR agonists (Table 1), we hypothesized that CaSR agonist peptides, such as γ-Glu-Val-Gly, might impart a *kokumi* taste.

In this report, we showed that CaSR agonists, including calcium, are possible appetite stimulants that enhance basic tastes by providing a *kokumi* taste and demonstrate that the CaSR is involved in human *kokumi* taste perception. CaSR agonists may directly activate the CaSR expressed on the surface of taste cells, and subsequently be integrated in the brain through the central nervous system. Until now, the physiological roles of calcium appetite were less well understood than those of other appetites. Some behavioral studies have focused on characterizing the specificity of the calcium appetite, and many behavioral experimental data on rats and mice are available, though the data are scarce for humans.

Attempts have been made to develop *kokumi* taste ingredients for commercial use, from natural products, such as autolyzed yeast extracts and hydrolyzed vegetable proteins(24); however, there are few examples of the isolation of pure *kokumi* taste substances. Recently, new *kokumi* taste substances have been isolated from an extract of edible beans, and these have been
characterized by human sensory analysis(10). The active substances were identified as the γ-Glu dipeptides, γ-Glu-Val and γ-Glu-Leu, which appear in the list of CaSR agonist peptides that we identified (Table 1). These γ-Glu peptides are also found in beech fruit(25) and in the bovine brain(26); γ-Glu-Cys is present in yeast extracts(27). The identification of the kokumi taste receptor allowed us to screen for new kokumi taste substances, using in vitro high-throughput assay methods. These kokumi taste substances are useful as taste enhancers in many kinds of food.

Wang et al. reported that GSH does not directly activate the CaSR but potentiates calcium-induced responses(28). They showed that GSH does not activate the CaSR in an assay buffer containing 0.5 mM calcium, but activation occurred under similar conditions when the assay buffer was supplemented with an additional 0.3 mM of calcium, administered simultaneously. In our study, GSH (data not shown) and γ-Glu-Val-Gly (Supplementary Fig. 2) activated the CaSR in an assay buffer of ≥ 0.75 mM calcium; thus suggesting that a certain basal level of calcium, corresponding to a physiological concentration, is necessary for activation of the CaSR by γ-Glu peptides. γ-Glu peptides such as γ-Glu-Val-Gly may act as partial allosteric agonists in a physiological environment, including plasma and saliva, in which calcium concentration is about 0.75 mM or more.

CaSR gene expression in taste buds was investigated using mouse tissue specimens. RT-PCR analyses showed that the CaSR mRNA was expressed in taste buds containing circumvallate and foliate papillae epithelium (Supplementary Fig. 3). However, RT-PCR products for the CaSR were not found in the epithelium surrounding the papillae. The same results were shown by immunohistological observation of rat and mouse taste buds(29). Among the class C GPCRs, the CaSR has the highest homology with GPRC6A. It has been reported that a chimeric receptor, consisting of the goldfish 5.24 (mammalian GPRC6A homolog) outer membrane domain and the mouse GPRC6A trans and intramembrane domains, is activated by GSH, but that neither a chimeric receptor consisting of a GPRC6A outer membrane domain and 5.24 trans- and intra-membrane domains nor full-length GPRC6A itself are functionally active(28). Wellendorph et al. reported that GPCR6A is expressed in rat taste buds-containing epithelia(30). However, in our experiment, GPRC6A mRNA expression was not detected in circumvallate and foliate epithelia from adult mice. These findings suggest that kokumi taste is mediated by CaSR activation, and it is unlikely that GPRC6A is involved in human taste perception.

Overall, our results show that CaSR agonists are recognized by CaSR in taste cells, and produce a desirable kokumi taste sensation in humans. Various kinds of CaSR agonists, including calcium, exist widely in nature, and are found in plants, animals, and microbes. The involvement of calcium in taste perception has been previously
suggested by some behavioral studies on mice that focused on calcium appetite, from which the involvement of T1R3 in calcium and magnesium recognition was proposed (31). No previous research has established direct evidence for the involvement of the CaSR in human taste perception. In addition to being expressed in taste buds, the CaSR is also expressed in the gastrointestinal tract (32,33), thus suggesting that CaSR agonists present in foodstuffs, such as cations, amino acids, and peptides, could be determinants of physiological processes such as motility, digestion, absorption, and secretion. Taken together, our findings indicate that there is an appetite for CaSR agonists in humans and highlight the importance of further detailed studies to elucidate the physiological significance of the palatability of kokumi taste substances in humans.

REFERENCES

1. Brown, E. M., Gamba, G., Riccardi, D., Lombardi, M., Butters, R., Kifor, O., Sun, A., Hediger, M. A., Lytton, J., and Hebert, S. C. (1993) Nature 366(6455), 575-580
2. Chattopadhyay, N., Vassilev, P. M., and Brown, E. M. (1997) Biol Chem 378(8), 759-768
3. Brown, E. M., and MacLeod, R. J. (2001) Physiol Rev 81(1), 239-297
4. Conigrave, A. D., Quinn, S. J., and Brown, E. M. (2000) Proc Natl Acad Sci USA 97(9), 4814-4819
5. Conigrave, A. D., and Hampson, D. R. (2006) Trends Endocrinol Metab 17(10), 398-407
6. McCaughhey, S. A., Forestell, C. A., and Tordoff, M. G. (2005) Physiol Behav 84(2), 335-342
7. Reed, D. R., Li, X., McDaniel, A. H., Lu, K., Li, S., Tordoff, M. G., Price, R. A., and Bachmanov, A. A. (2003) Mamm Genome 14(5), 302-313
8. Tordoff, M. G., Reed, D. R., and Shao, H. (2008) Genes Brain Behav
9. Ueda, Y., Sakaguchi, M., Hirayama, K., Miyajima, R., and Kimizuka, A. (1990) Agric Biol Chem 54(1), 163-169
10. Ueda, Y., Yonemitsu, M., Tsubuku, T., Sakaguchi, M., and Miyajima, R. (1997) Biosci Biotechnol Biochem 61(12), 1977-1980
11. Dunkel, A., Koster, J., and Hofmann, T. (2007) J Agric Food Chem 55(16), 6712-6719
12. Toelstede, S., Dunkel, A., and Hofmann, T. (2009) J Agric Food Chem 57(4), 1440-1448
13. Rodriguez, M., Nemeth, E., and Martin, D. (2005) Am J Physiol Renal Physiol 288(2), F253-264
14. Rybczynska, A., Lehmann, A., Jurska-Jasko, A., Boblewski, K., Orelwksa, C., Foks, H., and Drewnowska, K. (2006) J Endocrinol 191(1), 189-195
15. Zhang, Y., Chen, M., and Ho, C. (1988) J Agric Food Chem 36, 992-996
16. Mecchi, E. P., Pippen, E. L., and Lineweaver, H. (1964) J. Food Sci. 29, 393-399
17. Hoon, M. A., Adler, E., Lindemeier, J., Battey, J. F., Ryba, N. J., and Zuker, C. S. (1999) 
   *Cell* **96**(4), 541-551
18. Nelson, G., Hoon, M. A., Chandrashekar, J., Zhang, Y., Ryba, N. J., and Zuker, C. S. (2001) 
   *Cell* **106**(3), 381-390
19. Nelson, G., Chandrashekar, J., Hoon, M. A., Feng, L., Zhao, G., Ryba, N. J., and Zuker, C. S. (2002) 
   *Nature* **416**(6877), 199-202
20. Chandrashekar, J., Mueller, K. L., Hoon, M. A., Adler, E., Feng, L., Guo, W., Zuker, C. S., 
   and Ryba, N. J. (2000) *Cell* **100**(6), 703-711
21. Adler, E., Hoon, M. A., Mueller, K. L., Chandrashekar, J., Ryba, N. J., and Zuker, C. S. 
   (2000) *Cell* **100**(6), 693-702
22. Rotin, D., Bar-Sagi, D., O'Brodovich, H., Merilainen, J., Lehto, V. P., Canessa, C. M., 
   Rossier, B. C., and Downey, G. P. (1994) *Embo J* **13**(19), 4440-4450
23. Ishimaru, Y., Inada, H., Kubota, M., Zhuang, H., Tominaga, M., and Matsunami, H. (2006) 
   *Proc Natl Acad Sci U S A* **103**(33), 12569-12574
24. Aaslyng, M. D., Martens, M., Poll, L., Nielsen, P. M., Flyge, H., and Larsen, L. M. (1998) 
   *J Agric Food Chem* **46**(2), 481-489
25. Kristensen, I., Larsen, P., and Sørensen, H. (1974) *Phytochemistry* **13**(12), 2803-2811
26. Kanazawa, A., Kakimoto, Y., Nakajima, T., and Sano, I. (1965) *Biochim Biophys Acta*
   **111**(1), 90-95
27. Li, Y., Wei, G., and Chen, J. (2004) *Appl Microbiol Biotechnol* **66**(3), 233-242
28. Wang, M., Yao, Y., Kuang, D., and Hampson, D. R. (2006) *J Biol Chem* **281**(13), 8864-8870
29. San Gabriel, A., Uneyama, H., Maekawa, T., and Torii, K. (2009) *Biochem Biophys Res Commu*
   **378**(3), 414-418
30. Wellendorph, P., Burhenne, N., Christiansen, B., Walter, B., Schmale, H., and 
   Brauner-Osborne, H. (2007) *Gene* **396**(2), 257-267
31. Tordoff, M. G., Shao, H., Alarcon, L. K., Margolskee, R. F., Mosinger, B., Bachmanov, A. A., 
   Reed, D. R., and McCaughey, S. A. (2008) *Physiol Genomics*
32. Hebert, S. C., Cheng, S., and Geibel, J. (2004) *Cell Calcium* **35**(3), 239-247
33. Conigrave, A. D., and Brown, E. M. (2006) *Am J Physiol Gastrointest Liver Physiol* **291**(5), 
   G753-761
34. Scheffer, H. (1952) *J Am Stat Ass* **47**, 381-400

**FOOTNOTES**

*Acknowledgments*—The authors sincerely thank to Yasuhiro Uezono and Seiji Fukumoto for 
valuable comments on electrophysiology and CaSR, respectively. We would like to thank 
Kiyoshi Miwa, Tohru Kouda and Hiroaki Takino for their encouragement and continued
support of this work. We are grateful to Hisashi Uneyama, Chiori Ijichi, Mitsuo Takahashi, Sayaka Asari, Kaoru Takenaka, Reiko Yasuda, Seiichi Sato, Megumi Kaneko, Takako Hirose, Orie Yokoi and Yasuhsisa Manabe for their helpful discussions and assistance. We are also grateful to members of the taste panel at the Food Products Global R&D Center in Ajinomoto Co., INC.

FIGURE LEGENDS

**Fig. 1.** Time-course profiles of kokumi taste of GSH and γ-Glu-Val-Gly

GSH (0.1%; a control kokumi taste substance) and γ-Glu-Val-Gly (0.01%; a newly discovered peptide) were determined by human sensory analyses performed in a blind test. The taste enhancement intensity was expressed as a percentage score in comparison with the maximum intensity obtained with a standard solution containing 0.07% monosodium glutamate (MSG), 0.07% inosine monophosphate (IMP), and 0.7% NaCl, which was taken as 100%. (a) low concentrations of umami and salty tastes (0.02% MSG, 0.02% IMP, and 0.07% NaCl); (b) solution (a) plus 0.08% GSH; (c): solution a plus 0.01% γ-Glu-Val-Gly. Data are shown as averages (n = 20) with error bars (standard error of the mean [SEM]). Solutions (b) and (c) were significantly stronger than (a) at 5 s (p < 0.01) and 20 s (p < 0.05).

**Fig. 2.** Human sensory analyses for kokumi taste of GSH and γ-Glu-Val-Gly

A. Kokumi taste intensity of GSH and γ-Glu-Val-Gly for each basic taste was determined. In this experiment, GSH (0.1%) and γ-Glu-Val-Gly (0.01%) were mixed independently with sucrose (3.3%), NaCl (0.9%), or MSG (0.5%). Kokumi taste was rated on a 5-point scale (ranging from −2 [apparently suppressed] to +2 [apparently strong]) in terms of thickness, i.e., taste enhancement approximately 5 s after tasting(9,34). Human sensory analyses were performed in a blind test by a panel of 20 well-trained assessors, and the results were analyzed by the Student’s t-test. Data are shown as averages (n = 20) with error bars (SEM). Asterisks indicate significant differences (Student’s t-test) from the control; * p < 0.05, ** p < 0.01, and *** p < 0.001.

B. Kokumi taste profiles of GSH and γ-Glu-Val-Gly for chicken consommé were evaluated as follows. GSH (0.02%), γ-Glu-Val-Gly (0.002%), and γ-Glu-Val-Leu (0.02%; a low-activity control peptide) were dissolved in chicken consommé prepared with 2% of a commercial chicken consommé powder. Human sensory analyses were performed with a focus on kokumi taste characteristics, i.e., thickness, continuity, and mouthfulness (materials and methods). Kokumi taste was evaluated in a blind test on a 5-point rating scale for the three paired scale terms. Data are shown as averages (n = 20) with error bars (SEM). Asterisks indicate significant differences (Student’s t-test) from the control; * p < 0.05, ** p < 0.01, and *** p <
0.001.

Fig. 3. Correlation between calcium-sensing receptor (CaSR) activity and kokumi taste intensity
A. HEK-293 cells transiently expressing human-CaSRs were used in the calcium imaging method, and the dose dependence was analyzed for six CaSR agonist peptides. Effective concentration (EC50) values were determined as follows: γ-Glu-Ala (a, 3.65 µM/42.6 = Emax); γ-Glu-Val (b, 1.34 µM/53.3); γ-Glu-Cys (c, 458 nM/38.0); γ-Glu-Cys-Gly [glutathione (GSH), 76.5 nM/27.6]; γ-Glu-Abu-Gly (d, 18.1 nM/25.6); and γ-Glu-Val-Gly (e, 41.9 nM/40.8). γ-glutamyl (γ-Glu) peptides showed 26–53% of the maximum intensity (Emax) observed with Ca2+ (calcium = 100%).

B. Relationship between CaSR activity (Fig. 3A, EC50) and kokumi taste intensity (Table 1) of five γ-Glu peptides plotted on logarithmic scales in comparison with GSH. A Pearson correlation coefficient was used to calculate the relationship between CaSR activity and kokumi taste intensity. A significant positive correlation was found (r² = 0.660, p = 0.0496).

C. There was a strong inhibitory effect of the CaSR antagonist. The CaSR activity dose response of γ-Glu-Val-Gly was analyzed with HEK-293 cells transiently expressing human-CaSR mRNA in the absence and presence of NPS-2143 (5 µM).

Fig. 4. Kokumi taste profiles of known CaSR agonists and an antagonist
A. Human sensory analyses of the CaSR agonists were performed to determine the kokumi taste with known CaSR agonists. CaSR agonists were mixed with a control solution of MSG (0.1%) and NaCl (0.5%) at the following concentrations: GSH (0.08%; control kokumi taste substance), calcium lactate (0.35%), protamine (0.02%), polylysine (0.08%), L-histidine (0.2%), cinacalcet (0.0015%), γ-Glu-Val-Gly (0.01%), and γ-Glu-Val-Leu (0.08%; a low-activity control peptide). Human sensory analyses were performed in a blind test focusing on one of the kokumi taste characteristics, i.e., thickness. Data are shown as average scores (n = 20) with error bars (SEM). Asterisks indicate significant differences (Student’s t-test) from the control; * p < 0.05, ** p < 0.01, and *** p < 0.001.

B. Human sensory analyses of CaSR agonists were performed to determine kokumi taste in the presence or absence of a CaSR antagonist (NPS-2143), using the method described in Fig. 3A. The concentrations used in this experiment were GSH (0.08%), γ-Glu-Val-Gly (0.01%), and NPS-2143 (0.0002%; 4.5 µM). Data are shown as average scores (n = 20) with error bars (SEM). Asterisks indicate significant differences (Student’s t-test) from NPS-2143; * p < 0.05, ** p < 0.01, and *** p < 0.001.
Table 1. Determination of calcium-sensing receptor (CaSR) activity using *Xenopus* oocytes

| No | γ-Glutamyl Peptides   | CaSR Activity (µM) | No | γ-Glutamyl Peptides   | CaSR Activity (µM) |
|----|----------------------|--------------------|----|----------------------|--------------------|
| 1  | γ-Glu-Gly            | 1000               | 24 | γ-Glu-Ile-Gly        | 100                |
| 2  | γ-Glu-Val-NH2        | 1000               | 25 | γ-Glu-Cys(S-allyl)-Gly| 100                |
| 3  | γ-Glu-Val-ol         | 1000               | 26 | γ-Glu-Val-His        | 100                |
| 4  | γ-Glu-Met(O)         | 1000               | 27 | γ-Glu-Val-Orn        | 100                |
| 5  | γ-Glu-Val-Val        | 1000               | 28 | γ-Glu-Ala            | 50 (3.7*)           |
| 6  | γ-Glu-Val-Glu        | 1000               | 29 | γ-Glu- thr           | 50                 |
| 7  | γ-Glu-Val-Lys        | 1000               | 30 | γ-Glu-Cys(S-Me)      | 30                 |
| 8  | γ-Glu-Val-Arg        | 1000               | 31 | γ-Glu-Cys-Gly        | 30                 |
| 9  | γ-Glu-Val-Asp        | 1000               | 32 | γ-Glu-Val-Phe        | 30                 |
| 10 | γ-Glu-Val-Met        | 1000               | 33 | γ-Glu-Val-Ser        | 30                 |
| 11 | γ-Glu-Val-Thr        | 1000               | 34 | γ-Glu-Val-Pro        | 30                 |
| 12 | γ-Glu-Met            | 500                | 35 | γ-Glu-Val-Asn        | 30                 |
| 13 | γ-Glu-Orn            | 500                | 36 | γ-Glu-Val            | 10 (1.6*)           |
| 14 | γ-Glu-Ser            | 300                | 37 | γ-Glu-Ala-Gly        | 10                 |
| 15 | γ-Glu-Tau            | 300                | 38 | γ-Glu-Ser-Gly        | 10                 |
| 16 | γ-Glu-Leu-Gly        | 300                | 39 | γ-Glu-Val-Gln        | 10                 |
| 17 | γ-Glu-Thr-Gly        | 300                | 40 | γ-Glu-Val-Cys        | 10                 |
| 18 | γ-Glu-Pro-Gly        | 300                | 41 | γ-Glu-Cys            | 3 (0.46*)           |
| 19 | γ-Glu-Val-Ala        | 300                | 42 | γ-Glu-Cys-Gly (GSH)  | 3 (0.71*)           |
| 20 | γ-Glu-Cys(S-Me)(O)   | 300                | 43 | γ-Glu-Abu-Gly        | 3 (0.025*)          |
| 21 | γ-Glu-Leu            | 100                | 44 | γ-Glu-Cys(S-Me)-Gly  | 3                  |
| 22 | γ-Glu-Ile            | 100                | 45 | γ-Glu-Cys(SNO)-Gly   | 3                  |
| 23 | γ-Glu-tLeu           | 100                | 46 | γ-Glu-Val-Gly        | 0.1 (0.039*)        |

A Two-electrode voltage-clamp assay was performed using oocytes microinjected with human-CaSR cRNA at −70 mV. Peptides were added at various concentrations (1000, 500, 300, 100, 50, 30, 10, 3, 1, 0.3, and 0.1 µM), and the minimum effective concentration at which a current was detected was a measure of the strength of CaSR activation. The results show that 46 gamma-glutamyl peptides had CaSR activity. No response was observed in oocytes injected with distilled water as a control. In comparison, EC50 values (µM) for 6 peptides determined by HEK assay were shown in the table (*). The HEK assay gave a higher sensitivity than the oocyte assay.
Table 2. Quantitative analyses of the *kokumi* taste intensity of gamma-glutamyl peptides

| Sample Concentration (%) (A) | GSH Concentration for PSE (%) (B) | Kokumi Taste Intensity Compared with GSH (C) |
|------------------------------|----------------------------------|--------------------------------------------|
| GSH (γ-Glu-Cys-Gly)          | —                                | 1                                          |
| γ-Glu-Ala (a)                | 0.5                              | 0.074                                      | 0.15                                      |
| γ-Glu-Val (b)                | 0.15                             | 0.092                                      | 0.61                                      |
| γ-Glu-Cys (c)                | 0.15                             | 0.094                                      | 0.63                                      |
| γ-Glu-Abu-Gly (d)            | 0.05                             | 0.085                                      | 1.7                                       |
| γ-Glu-Val-Gly (e)            | 0.01                             | 0.128                                      | 12.8                                      |

A quantitative evaluation of the human sensory analyses was performed by a panel of 17 well-trained assessors, who judged the point of subjective equality (PSE) between sample and reference GSH solutions. A series of GSH concentrations were chosen in logarithmically equal steps at 50% intervals (0.02, 0.03, 0.044, 0.07, 0.10, 0.15, 0.23, and 0.34% w/v). Each test sample was paired twice with the reference GSH solution, and the assessors were required to rate the sensation produced by a test sample as either more or less intense than that of the reference solution. The PSE was defined as the concentration that was judged to produce a sensation equal to that of the standard solution. (A) Sample concentration was determined by preliminary tests. (B) PSE, point of subjective equality. (C) A/B. Data were analyzed by means of the probit method.
Fig. 1

![Graph](image)

- a: Low MSG + IMP + NaCl
- b: + 0.08% γECG (GSH)
- c: + 0.01% γEVG

Taste Intensity (% of Max)

Time (sec)
Fig. 2

A

Taste Enhancement Intensity (Human Sensory Analysis Score)

- Sweet
- Salty
- Umami

Control
- 0.1% ΥECG (GSH)
- 0.01% ΥEVG

***

B

Taste Enhancement Intensity (Human Sensory Analysis Score)

- γECG (GSH) 0.02%
- γEVG 0.002%
- γEVL 0.02%

Thicknes
- Continuity
- Mouthfulness

*
Fig. 3

A

CaSR Activity (Fluorescent intensity, %)

- Ca-Lactate
- γEA (a)
- γEV (b)
- γEC (c)
- γECG (GSH)
- γEAG (d)
- γEVG (e)

log (μM)

RFU (max. - min.)

0 10000 20000 30000 40000 50000 60000

B

Kokumi Taste Intensity

0 1

CaSR Agonist Activity

-1 0 1

GSH

C

CaSR Activity (Fluorescent intensity, %)

-3 -2 -1 0

γEVG

γEVG + NPS-2143 (5 μM)

log (μM)
Fig. 4

A

Taste Enhancement Intensity
(Human Sensory Analysis Score)

γ-ECG (GSH) 0.08%
Ca-Lactate 0.35%
Proline 0.02%
Poly-Lysine 0.08%
L-His 0.2%
Cineole 0.0015%
γ-EVG 0.01%
γ-EVL 0.08%

***
***
***
***
***
***

B

Taste Enhancement Intensity
(Human Sensory Analysis Score)

γ-ECG (GSH) 0.08%
γ-EVG 0.01%
NPS-2143 0.0002% (4.5 μM)

− + − +

* ***
Involvement of the calcium-sensing receptor in human taste perception
Takeaki Ohsu, Yusuke Amino, Hiroaki Nagasaki, Tomohiko Yamanaka, Sen Takeshita,
Toshihiko Hatanaka, Yutaka Maruyama, Naohiro Miyamura and Yuzuru Eto
J. Biol. Chem. published online November 5, 2009

Access the most updated version of this article at doi: 10.1074/jbc.M109.029165

Alerts:
• When this article is cited
• When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

Supplemental material:
http://www.jbc.org/content/suppl/2009/11/05/M109.029165.DC1